These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 27769356)
1. Suppression of T Ghosh S; Lora JM Drug Discov Today Technol; 2016 Mar; 19():39-44. PubMed ID: 27769356 [TBL] [Abstract][Full Text] [Related]
2. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791 [TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain as a Target of Epigenetic Therapy. Noguchi-Yachide T Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788 [TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis provides a BRD's eye view of BET protein function. Stonestrom AJ; Hsu SC; Werner MT; Blobel GA Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353 [TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibition suppresses TH17-mediated pathology. Mele DA; Salmeron A; Ghosh S; Huang HR; Bryant BM; Lora JM J Exp Med; 2013 Oct; 210(11):2181-90. PubMed ID: 24101376 [TBL] [Abstract][Full Text] [Related]
6. Targeting BET bromodomains for cancer treatment. Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433 [TBL] [Abstract][Full Text] [Related]
7. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842 [TBL] [Abstract][Full Text] [Related]
8. BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice. Cheung K; Lu G; Sharma R; Vincek A; Zhang R; Plotnikov AN; Zhang F; Zhang Q; Ju Y; Hu Y; Zhao L; Han X; Meslamani J; Xu F; Jaganathan A; Shen T; Zhu H; Rusinova E; Zeng L; Zhou J; Yang J; Peng L; Ohlmeyer M; Walsh MJ; Zhang DY; Xiong H; Zhou MM Proc Natl Acad Sci U S A; 2017 Mar; 114(11):2952-2957. PubMed ID: 28265070 [TBL] [Abstract][Full Text] [Related]
9. BET bromodomain inhibitors: a patent review. Garnier JM; Sharp PP; Burns CJ Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714 [TBL] [Abstract][Full Text] [Related]
10. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors. Sasaki K; Yoshida M Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358 [TBL] [Abstract][Full Text] [Related]
11. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. Albrecht BK; Gehling VS; Hewitt MC; Vaswani RG; Côté A; Leblanc Y; Nasveschuk CG; Bellon S; Bergeron L; Campbell R; Cantone N; Cooper MR; Cummings RT; Jayaram H; Joshi S; Mertz JA; Neiss A; Normant E; O'Meara M; Pardo E; Poy F; Sandy P; Supko J; Sims RJ; Harmange JC; Taylor AM; Audia JE J Med Chem; 2016 Feb; 59(4):1330-9. PubMed ID: 26815195 [TBL] [Abstract][Full Text] [Related]
14. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. Yang CY; Qin C; Bai L; Wang S Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490 [TBL] [Abstract][Full Text] [Related]
16. Clinical trials for BET inhibitors run ahead of the science. Andrieu G; Belkina AC; Denis GV Drug Discov Today Technol; 2016 Mar; 19():45-50. PubMed ID: 27769357 [TBL] [Abstract][Full Text] [Related]
17. Advancements in the Development of non-BET Bromodomain Chemical Probes. Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862 [TBL] [Abstract][Full Text] [Related]
18. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780 [TBL] [Abstract][Full Text] [Related]
19. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]